The Karma research group at Karolinska Institutet is creating the world’s best-characterised breast cancer cohort. The aim is to reduce the mortality and incidence in breast cancer through translational research focusing on breast cancer screening and prevention.

READ MORE ABOUT THE KARMA STUDY

The Karma research group at Karolinska Institutet is creating the world’s best-characterised breast cancer cohort. The aim is to reduce the mortality and incidence in breast cancer through translational research focusing on breast cancer screening and prevention.

READ MORE ABOUT THE KARMA STUDY

Recent news

2020-01-31

Karisma 2 Biopsy study on low-dose tamoxifen

Analyses are ongoing in the Karisma 2 Biopsy study. Karisma 2 Biopsy is a nested cohort within the Karisma 2 clinical trial on low-dose tamoxifen, conducted during 2017-2019 in Sweden. In all, 96 participants donated breast biopsied before and after treatment with tamoxifen or placebo. Analyses are ongoing and results are expected after the summer. 
2019-11-10

Karisma 2 clinical trial on low-dose tamoxifen is completed

We have now completed the Karisma 2 randomised clinical trial on low-dose tamoxifen. In all, 1,440 women were included in the Swedish two-centre study, at Södersjukhuset in Stockholm and at Unilabs in Lund.  The results are being analysed and the first paper is expected to be published after the summer 2020.  Karisma-2 is a dose optimisation...
2019-07-12

Papers on Mammographic Density Change and breast cancer

Doctoral student Shadi Azam has recently published two papers investigating mammographic density change using the KARMA cohort.
More news
LOG IN

Log in to the Karma Research Platform here

Not a member? REGISTER HERE...
Interview

Professor Per Hall talks about Karma